PlainPill

MK-2866 vs RAD-140 for weight loss

Short answer: For weight loss, users rate them about the same: 89% report improvement with MK-2866 (80 reports) and 92% with RAD-140 (51 reports).

MK-2866 has 0 meta-analyses and 0 randomized trials on PubMed; RAD-140 has 0 and 0.

Based on 612 reports about MK-2866 and 684 about RAD-140. Not medical advice.

MK-2866
SARM
RAD-140
SARM
User score3344
Verdict
Mixed
Mixed
Positive
of reports that state an outcome
39%42%
Reports612684
ResearchDResearch: NoneDResearch: None
Meta-analyses / RCTs0 / 00 / 0
Mainly used for
Weight loss
% reporting improvement
89% (80)92% (51)
Appetite
% reporting improvement
62% (8)56% (9)
Focus
% reporting improvement
71% (7)17% (6)
Energy
% reporting improvement
54% (37)41% (51)
Sleep
% reporting improvement
20% (20)3% (39)
Anxiety
% reporting improvement
33% (9)7% (15)
Mood
% reporting improvement
63% (49)37% (52)
Memory
% reporting improvement
—100% (2)
Performance
% reporting improvement
88% (192)93% (296)
Recovery
% reporting improvement
97% (60)96% (28)
Pain & inflammation
% reporting improvement
70% (27)17% (12)
Digestion
% reporting improvement
—0% (3)
Libido
% reporting improvement
31% (45)42% (38)
Hormones
% reporting improvement
4% (82)5% (62)
Heart & lipids
% reporting improvement
0% (8)6% (32)
Skin & hair
% reporting improvement
33% (6)0% (11)
Common side effectssuppression, fatigue, insomnia, headachesuppression, hair loss, fatigue, insomnia
Typical dose reportedNot listedNot listed
MK-2866
What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
Full MK-2866 profile →
RAD-140
What a user said
“I did put on decent size and I feel a lot fuller. My strength and endurance has gone up tremendously. Side effects - Shedding of hair, anxiety...”
Full RAD-140 profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate